Potensi Pemeriksaan PA dalam Pemeriksaan Tahap Lanjutan pada Terapi Kanker Paru




Lung cancer which found mostly in men has been one of problematic diseases in the world as well as in Indonesia. It is currently stated as a disease with the highest death rate. Pollutants and smoking habits are two main causes of lung cancer that researchers have found. The world’s improvement in the study of carcinogenesis and molecular protein bring impacts in the study of lung cancer. Research findings of protein inhibitor to carcinogenesis and new proteins become defiances to the existing therapy that convey great challenges, yet bring a new hope in giving specific therapy through molecular approach. This approach closely relates to genomic projects and has more moderate form of derivation in anatomy pathology examination. Examination technology advance in several researches shows little hopes in giving lung cancer patients’ longer lifespan which are not completely satifsying.

This study aims to give broader insights and an identifier to a more sustain advanced anatomy pathology in determining targeted theraphy and in decision making on giving chemoteraphy medicine. Therefore, chemotheraphy medicines/treatments will not merely be based only on clinical reasons, but also use more molecular protein approach individually.

Keyword: Lung cancer, theraphy, molecular protein

Full Text:



Almira tsania Gita, 2018. Farmakogenomik Non-small cell lung cancer’ Farmaka suplemen vol 16 no2: 457-462.

Freddie Bray, Jacques Ferla, Isabelle Soerjomataram, Rebecca L. Siegel, Lindsey A. Torre, Ahmedin Jemal. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. : A Cancer Journal for Clinicians 2019: Volume 68, Issue 6

Gong W, Zhang X, Wu J, Chen L, Li L, Sun J, Lv Y, Wei X, Du Y, Jin H. Dong 2012. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis J. Lung Cancer. Mar;75(3):374-80.

Guenaelle Levallet, Emmanuel Bergot, Martine Antoine, Christian Creveuil, Adriana O.Santos, Michelle Beau-Faller, Florence de Fraipont, Elisabeth Brambilla,Jerome Levallet, Franck Morin, Virginie Westeel, Marie Wislez, Elisabeth Quoix, Didier Debieuvre16, Fatemeh Dubois, Isabelle Rouquette, Jean-LouisPujol, DenisMoro-Sibilot ,JacquesCamonis, GerardZalcman, onbehalfoftheIntergroupe Francophone de Cancerologie Thoracique (IFCT) 2012. High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway Mol Cancer Ther: 11(5) 1203-1213Hassan Lemjabbar-Alaoui, Omer Hassan, Yi-Wei Yang and Petra Buchanan 2015. Lung cancer: biology and treatment options. Biochim Biophys Acta. 1856(2):189-210.

Kehua Wu, Larry House, WAnqing Liu and William C.S.Cho 2012. Personalized Targeted Therapy for Lung Cancer. Int.J.Mol.Sci. 12(9):11471-11496.

KEMENKES RI (2017). PEDOMAN NASIONAL PELAYANAN KEDOKTERAN KANKER PARU. Jakarta: kementrian kesehatan RI. http://kanker.kemkes.go.id/guidelines/PNPKParu.pdf

Ken A. Olausse, Ariane Dunant, Pierre Fouret, Elisabeth Brambilla, Fabrice André, Vincent Haddad, M.S., Estelle Taranchon, M.S., Martin Filipits, Robert Pirker, Helmut H. Popper, Rolf Stahel, Laure Sabatier, Jean-Pierre Pignon, Thomas Tursz, Thierry Le Chevalier and Jean-Charles Soria.et al., for the IALT Bio Investigators 2006. DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy N Engl J Med; 355:983-991.

Martin K.H. Maus, Philip C.Mack, Stephanie H.Astrow, Craig L.Stephens, Gary D.Zeger, Peter P,Grimminger, Jack H. Hsiang, Eric Huang, Tianghong Li, Primo N.Lara, Kathleen D.Danenberq dan David R. Gandara 2013. Histologi-Related Asssocitaions of ERCC1, RRM1 and TS Biomarkers in Patients with Non-Small-Cell-Lung-Cancer implications for theraphy. J.of thoracic onvology:8(5) 582-586.

Mihoko A. Tame, Anna G. Manjón, Daria Belokhvostova, Jonne A. Raaijmakers1 and René H. Medema 2016. TUBB3 overexpression has a negligible effect on the sensitivity to taxol in cultured cell lines. Oncotarget, 2017, Vol. 8, (No. 42) 71536-71547.

Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R and Gandhi V 1995. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.. Semin Oncol. 1995 Aug;22(4 Suppl 11):3-10.

Rosai Juan. 2011. Surgical Pathology ed 10: Elsevier, USA. 366-378

Shaloam Dasari and Paul Bernard Tchounwou 2014. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014 October 5; 0: 364–378.

Siow ming lee, Mary Faizon, Fiona Blackhall, James Spicer, Marianne Nicholson, Abhro Chaudhuri 2017. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Theraphy in Advanced Non-small Cell Lung Cancer: ERCC1 Trial (ET)’, J. of Clinical Oncology; 35:4:402-411.

Stefan Hammerschimidt, Hubert Wirt 2009. Lung cancer: Current Diagnosis and treatment. Deutsches Ärzteblatt International | Dtsch Arztebl Int 2009; 106(49): 809–20

Vincent MD, M.S. Kuruvilla, N.B. Leighl, and S. Kamel–Reid 2012. Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Current oncology 19:833-844.

William D.Travis, Elisabeth Brambilla, Allen P.Burke, Alxander Marx, Andrewa G.Nicholson 2015. WHO classification of tumors of the Lung, Pleura, Thymus and Heart ed4: IARC, Lyon, 18-26.

Zhi-Liang Huang, Xun Cao, Ruo-Zhen Luo, You-Fang Chen, Lin-Chun Zhu, and Zhesheng Wen 2014. Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis ini patients with non-small cell lung cancer who received cisplatin based adjuvant chemotherapy: A prospective study. Oncology Letters 11: 299-305.

Zhong Zheng, Tingan Chen, Xuen Li, Eric HAura, and Gerold Bepler, et.al. 2007. DNA synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer’ N. Engl. J. Med.; 356:800-808.

Zou ZQ, Du YY, Sui G, Xu SN. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 2015. Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy’ Asian Pac J Cancer Prev. 2015;16(8):3189-94.


DOI: http://dx.doi.org/10.30649/htmj.v17i1.190


  • There are currently no refbacks.



sinta-logogarudagoogle onesearchroad


 Statistik Counter


Lisensi Creative Commons
Hang Tuah Medical Journal (Print ISSN: 1693-1238 | Online ISSN: 2598-4861) is licensed under a Lisensi Creative Commons Atribusi 4.0 Internasional. Published by Hang Tuah University Press, Surabaya, Indonesia.